Related Experiment Video
Updated: Oct 3, 2026

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
Published on: January 7, 2019
Cizolirtine. Laboratorios Dr Esteve
1Vemalis Research Ltd, Oakdene Court, 613 Reading Road, Winnersh, Wokingham, RG41 5UA, UK. n.monck@vemalis.com
Abstract:
Cizolirtine is a centrally-acting analgesic that is under development by Esteve for the potential treatment of pain [171179]. In March 2001, phase II and III trials in the US and Europe were ongoing [404223]. Its mechanism of action is based on the inhibition of substance P and calcitonin gene-related peptide release at the spinal cord level [404223] but this has not yet been fully confirmed. Cizolirtine does not produce gastrointestinal lesions or depress respiration [388894], however, it does exhibit antipyretic activity in animal models [260611], [388894]. The compound was disclosed in EP-00289380, published by Esteve in 1988. A method of resolving the racemic compound has also been claimed in WO-09902500.
More Related Videos
12:21Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
08:48In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Equivalents
Antiviral Nucleoside Inhibitors